Sunday, May 31, 2020

Novartis IVIVC (In Vitro In Vivo Correlation) Manager- Respiratory (Pharmacy or Life science)


Novartis IVIVC (In Vitro In Vivo Correlation) Manager- Respiratory  (Pharmacy or Life science)

Job Description

1000 molecules belong to the department of clinical development (clinical due diligence and clinical research). You will chip in to the filling and maintenance of the portfolio by working closely with our business development team and other partners.

Your responsibilities include, but are not limited to:

•Responsible for chipping in and driving the clinical development strategy for respiratory drug products in close collaboration with the development and project teams. Responsible for review and update of the clinical development strategy as needed.

•Give good cross-functional understanding and experience of generic inhaler development and device technology to the project team. Responsible to work closely with technical development to link the technical and clinical expertise.

•Be familiar with characteristics of API, excipients and have understanding which parameters are affecting bioavailability; Preparation of bioequivalence risk assessment from literature data and in-vitro data

•Sound understanding of the challenges of the product and product development, e.g. influence of priming, determinant of in vitro variability between batches, particle size.

•Able to analyze and interpret in vitro study results and dossiers. Must have fair knowledge of in-vitro and in-vivo correlation and device mechanisms of orally inhaled products.

•Validated skills and abilities in quantifying in vitro determinants influencing in vivo exposures of orally inhaled products and in batch selection.

•Should have sound knowledge of application of tools like Win-Nonlin, Gastro-Plus, and IVIVC toolkit.

•Experience with different study types (e.g. pharmacokinetic studies, therapeutic endpoint studies and scintigraphy studies (preferable).

TO APPLY CLICK HERE

FOR MORE JOB UPDATES




JOIN IN GROUP FOR DAILY UPDATES


No comments:

Post a Comment